Skip to main content
×
×
Home

Polypharmacy: should we or shouldn't we?

  • Rajesh Rajpal (a1), Elizabeth Owens (a2) and MacDara McCauley (a3)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Polypharmacy: should we or shouldn't we?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Polypharmacy: should we or shouldn't we?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Polypharmacy: should we or shouldn't we?
      Available formats
      ×
Abstract
Copyright
References
Hide All
1 Taylor, D. Antipsychotic polypharmacy – confusion reigns. Psychiatrist 2010; 34: 41–3.
2 Lepping, P, Harbone, GC. Polypharmacy: how bad are we really? Psychiatrist 2010; 34: 208–9.
3 Odelola, D, Ranceva, N. Polypharmacy: saint or sinner? Psychiatrist 2010; 34: 354.
4 Langan, J, Shajahan, P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2010; 34: 5862.
5 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009.
6 Williams, L, Newton, G, Roberts, K, Finlayson, S, Brabbins, C. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002; 181: 184–7.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 6 *
Loading metrics...

Abstract views

Total abstract views: 15 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 22nd June 2018. This data will be updated every 24 hours.

Polypharmacy: should we or shouldn't we?

  • Rajesh Rajpal (a1), Elizabeth Owens (a2) and MacDara McCauley (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *